Drug reference
empagliflozin-metformin
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Drug class
Endocrine (Glycosurics)
Mechanism of action
Empagliflozin: Selective sodium-glucose transporter-2 (SGLT2) inhibitor; SGLT2 is expressed in the proximal renal tubules and is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Metformin: Decreases hepatic glucose production; decreases GI glucose absorption; increases target cell insulin sensitivity
Common side effects
- Female genital mycotic infections
- Decreased vitamin B12 levels
- Increased LDL-C
- Increased urination
- Male genital mycotic infections
- Dyslipidemia
- Urinary tract infection
Related conditions
Frequently asked questions
What drug class is empagliflozin-metformin?
empagliflozin-metformin belongs to: Endocrine.
How does empagliflozin-metformin work?
Empagliflozin: Selective sodium-glucose transporter-2 (SGLT2) inhibitor; SGLT2 is expressed in the proximal renal tubules and is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Metformin: Decreases hepatic glucose production; decreases GI glucose absorption; increases target cell insulin sensitivity
What are the common side effects of empagliflozin-metformin?
Female genital mycotic infections, Decreased vitamin B12 levels, Increased LDL-C, Increased urination, Male genital mycotic infections, Dyslipidemia, Urinary tract infection
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.